-

BostonGene Named One of Massachusetts Best Genetics and Bioinformatics Startups

 Criteria for Recognition Includes Exceptional Performance in Innovation, Growth, Management or Societal Impact

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, announced today that BestStartup.us had named BostonGene a top Massachusetts startup in two categories, “Genetics” and “Bioinformatics."

BestStartup.us evaluated companies on various criteria, including innovation, growth, management, or societal impact. BestStartup.us aims to highlight companies promoting innovative products and breakthrough ideas across the United States.

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to advance the standard of care, accelerate research, and improve economics. The BostonGene Tumor Portrait Test™, based on integrated genomic and transcriptomic analysis, propels precision medicine into daily clinical practice and supports physicians in actualizing personalized therapy for cancer patients. BostonGene collaborates with many of the leading cancer centers across the United States for research and clinical adoption.

“We are honored to receive this recognition from BestStartup.us,” said Erin O’Reilly, Senior Director, Marketing at BostonGene. “The acknowledgment validates our ongoing commitment to identify novel and personalized treatment options through next-generation multi-platform analytics, further advancing and optimizing outcomes for each cancer patient.”

About BostonGene Corporation

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.

Contacts

Media:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

Industry:

BostonGene Corporation

Release Versions
English

Contacts

Media:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

More News From BostonGene Corporation

Business Intelligence Group Names BostonGene Outstanding Organization and Double Winner in the 2026 Artificial Intelligence Excellence Awards

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI model for tumor and immune biology, today announced that it has been recognized as the Overall Winner in the 2026 Artificial Intelligence Excellence Awards by the Business Intelligence Group. The global program named BostonGene an Outstanding Organization, while simultaneously awarding top product honors for its multimodal AI platform. By integrating genomic, transcriptomic, immune profiling, imaging, and clinical data int...

BostonGene and Kyoto University Establish Strategic Partnership to Advance Biomarker Discovery for Combination Immunotherapy

TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI model for tumor and immune biology, today announced a strategic research partnership with Kyoto University, a research institution known for its groundbreaking advancements in medicine and science. The partnership supports a multicenter, Phase II clinical trial led by Dr. Manabu Muto of Kyoto University, evaluating the safety and efficacy of a combined therapeutic approach using immune checkpoint inhibitors (IC...

BostonGene Named “Overall AI-based Analytics Company of the Year” in 2026 AI Breakthrough Awards Program

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, leading developer of AI models for tumor and immune biology, today announced that it has been selected as winner of the “Overall AI-based Analytics Company of the Year” award in the 9th annual AI Breakthrough Awards program conducted by AI Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market today. For nearly a decade, the AI Breakthroug...
Back to Newsroom